Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
Status:
Unknown status
Trial end date:
2020-08-30
Target enrollment:
Participant gender:
Summary
ETP-ALL is a recently recognized high-risk subgroup and the optimal therapeutic approaches
are poorly characterized. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and
MRD-directed PDT-ALL-2016 protocol, this open-label, one-arm, multi-site trial is aimed to
evaluate the safety and effect of a novel oral histone deacetylase inhibitor chidamide for
adult ETP-ALL/LBL in CHINA.